852243-39-1|WT-1 A1|L-Leucine, L-tyrosyl-L-methionyl-L-phenylalanyl-L-prolyl-L-asparaginyl-L-alanyl-L-prolyl-L-tyrosyl-|-范德生物科技公司

WT-1 A1

NMR下载 COA and HPLC MSDS下载
names：
L-Leucine, L-tyrosyl-L-methionyl-L-phenylalanyl-L-prolyl-L-asparaginyl-L-alanyl-L-prolyl-L-tyrosyl-
CAS号：
852243-39-1
MDL Number：
MF(分子式)： C55H74N10O13S MW(分子量)： 1115.31
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	L-Leucine, L-tyrosyl-L-methionyl-L-phenylalanyl-L-prolyl-L-asparaginyl-L-alanyl-L-prolyl-L-tyrosyl-
英文别名	WT-1 A1; Tyr-Met-Phe-Pro-agn-Ala-Pro-Tyr-Leu;
CAS号	852243-39-1
SMILES	CC(C)C[C@@H](C(O)=O)NC([C@H](CC1=CC=C(O)C=C1)NC([C@H]2N(C([C@H](C)NC([C@H](CC(N)=O)NC([C@H]3N(C([C@H](CC4=CC=CC=C4)NC([C@H](CCSC)NC([C@H](CC5=CC=C(O)C=C5)N)=O)=O)=O)CCC3)=O)=O)=O)CCC2)=O)=O
Inchi	InChI=1S/C55H74N10O13S/c1-31(2)26-43(55(77)78)63-50(72)40(28-35-16-20-37(67)21-17-35)60-51(73)44-12-8-23-64(44)53(75)32(3)58-49(71)41(30-46(57)68)61-52(74)45-13-9-24-65(45)54(76)42(29-33-10-6-5-7-11-33)62-48(70)39(22-25-79-4)59-47(69)38(56)27-34-14-18-36(66)19-15-34/h5-7,10-11,14-21,31-32,38-45,66-67H,8-9,12-13,22-30,56H2,1-4H3,(H2,57,68)(H,58,71)(H,59,69)(H,60,73)(H,61,74)(H,62,70)(H,63,72)(H,77,78)/t32-,38-,39-,40-,41-,42-,43-,44-,45-/m0/s1
InchiKey	IBNSYSWDJJQKSY-PJYANRIDSA-N
分子式 Formula	C55H74N10O13S
分子量 Molecular Weight	1115.31
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	WT-1 A1(CAS:852243-39-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	WT-1 A1 is an attractive target for immunotherapy in patients with pancreatic adenocarcinoma.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Terashima T, Mizukoshi E, Arai K, Yamashita T, Yoshida M, Ota H, Onishi I, Kayahara M, Ohtsubo K, Kagaya T, Honda M, Kaneko S. P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma. Cancer Immunol Immunother. 2014 May;63(5):479-89. doi: 10.1007/s00262-014-1529-8. Epub 2014 Mar 16. PubMed PMID: 24633336.

[2]Asma GE, van den Bergh RL, Vossen JM. Characterization of early lymphoid precursor cells in the human fetus using monoclonal antibodies and anti-terminal deoxynucleotidyl transferase. Clin Exp Immunol. 1986 May;64(2):356-63. PubMed PMID: 3742878; PubMed Central PMCID: PMC1542329.

[3] Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, Ashizawa T, Yagoto M, Abe Y, Mitsuya K, Watanabe R, Sugino T, Yamaguchi K, Nakasu Y. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer. 2012 Dec 27;1

2:623. doi: 10.1186/1471-2407-12-623. PubMed PMID: 23270484; PubMed Central PMCID: PMC3541167.

[5] Adkins WK, Barnard JW, Moore TM, Allison RC, Prasad VR, Taylor AE. Adenosine prevents PMA-induced lung injury via an A2 receptor mechanism. J Appl Physiol (1985). 1993 Mar;74(3):982-8. PubMed PMID: 8387073.

5: Petrou M, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation. 1995 Nov 1;92(9 Suppl):II483-9. PubMed PMID: 7586459.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开